SAVA
Cassava Sciences, Inc.2.9300
+0.1300+4.64%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
141.54MP/E (TTM)
-Basic EPS (TTM)
-2.22Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Board adds commercialization expert
Cassava Sciences expanded its board to eight members and appointed Dawn C. Bir as a Class I director, effective October 21, 2025, to bolster strategic expertise ahead of its first simufilam clinical study for TSC-related epilepsy in early 2026. Bir's extensive background in biotech commercialization—from Reata's Biogen acquisition to leadership at Geron and Soleno—positions her to guide the company from clinic to market. This addition sharpens focus on value creation. Yet risks in drug development loom large.
8-K
Corporate presentation released
Cassava Sciences released its corporate presentation on September 8, 2025, under Regulation FD, detailing ongoing advancements in its Alzheimer's disease pipeline. The document, available on the company's website, highlights simufilam's Phase 3 trial progress and potential market positioning. Investors gain fresh insights into development timelines. No financial metrics or specific outcomes disclosed.
IPO
Employees
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
ATHE
Alterity Therapeutics Limited
3.07+0.06
AVXL
Anavex Life Sciences Corp.
4.02-0.12
BIVI
BioVie Inc.
1.43+0.00
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
IGC
IGC Pharma, Inc.
0.34+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
NERV
Minerva Neurosciences, Inc
4.17+0.13
SVRA
Savara, Inc.
6.43-0.18